Loading...
Loading...
The project aims to use advanced digital models to accelerate pharmaceutical research and development, reduce costs, and improve the accuracy of compound evaluation before manufacturing.
At the exhibition, EDE signed a Memorandum of Understanding with InSilico Medicine AI Limited to enhance collaboration and support the development of national capabilities in applying artificial intelligence to innovative medical product development.
The agreement was signed by Her Excellency Dr Fatima Al Kaabi, Director General of the Emirates Drug Establishment, and Dr Alex Aliper, President of InSilico Medicine AI Limited. Both parties said the partnership reflects a shared commitment to building a resilient healthcare ecosystem, strengthening pharmaceutical security, and reinforcing the UAE’s position as a regional hub for health technology innovation.
During the exhibition, EDE highlighted the project as a major step in digital transformation within drug development. The initiative uses generative AI and deep learning to assess drug efficacy before production, thereby reducing research costs and shortening the time needed for new therapies to reach patients.
Dr Shaikha Al Mazrouei, Director of the Reference National Laboratory Drug Department at EDE, said the collaboration will enable the deployment of advanced AI design platforms, using generative models and reinforcement learning, to analyse biological, chemical and clinical data.
She explained that these technologies enable more precise testing, the creation of optimised drug compounds and predictive toxicity studies, while reducing reliance on animal models during early development stages.
The initiative aligns with EDE’s strategy to advance pharmaceutical innovation, localise biotechnology industries, strengthen national manufacturing capabilities, and ensure the sustainable availability of high-quality medical products at competitive prices.
For an optimal experience, please
rotate your device to portrait mode.
